Zanubrutinib Approved for Relapsed/Refractory Marginal Zone Lymphoma

The FDA has granted accelerated approval to zanubrutinib (Brukinsa®, BeiGene) for the treatment of patients with relapsed/refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. "Marginal zone lymphoma is rare and heterogeneous, and it has been difficult to define optimal therapeutic strategies," wrote Stephen Opat, FRACP, FRCPA, MBBS, Director of Clinical Hematology at Monash Health in Australia, and colleagues, in their publication of the initial results...

Continue reading

Recent Advances in T-Cell Lymphoma: A Video Interview With Dr. Steven Horwitz

In this interview, Steven Horwitz, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, speaks with Oncology Data Advisor about the recent advancements in the treatment of T-cell lymphoma. Keira Smith: Hi, I'm Keira Smith from Oncology Data AdvisorTM. I'm here today with Dr. Steven Horwitz. Steven Horwitz, MD: Hi, pleasure to be here. I'm Dr. Steven Horwitz. I'm a medical oncologist at Memorial Sloan Kettering Cancer Center. Keira Smith: What do you consider some of the ...

Continue reading

Copyright © 2022 Oncology Data Advisor. All rights reserved.